




Goldman Sachs – 9th Annual European Medtech and Healthcare Services Conference

September 5 – 6, 2012



Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Frankfurt listing (DAX30): FRE
US ADR program (OTC): FSNUY

Sales 2011: €16.5 bn
EBIT 2011: €2,563 m



100%




Oncology and Immunology Therapies
EBIT 2011: -€30 m

31%

100%

100%


77%



Fresenius Medical Care

Dialysis Products,
Dialysis Care


Sales 2011: US\$12,795 m
EBIT 2011: US\$2,075 m



Fresenius Kabi

Infusion Therapy, IV Drugs,
Clinical Nutrition,
Medical Devices/
Transfusion Technology

Sales 2011: €3,964 m
EBIT 2011: €803 m



Fresenius Helios

Hospital Operations

Sales 2011: €2,665 m
EBIT 2011: €270 m




Fresenius Vamed

Engineering and Services
for Hospitals and
Other Health Care Facilities

Sales 2011: €737 m
EBIT 2011: €44 m

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE & Co. KGaA

Fresenius Group: Financial Results



Group financial results before APP-transaction-related special items

Fresenius Group: Financial Results

	Sales ¹	EBIT ²	Net income ³
H1/12	€9,236 m	€1,440 m	€434 m
Growth at constant currency rates	12%	14%	15%
Growth at actual currency rates	17%	19%	20%

¹ Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

² Adjusted for one-time costs of €7 million in Q2 2012 related to the offer to the shareholders of RHÖN-KLINIKUM AG.

³ Net income attributable to shareholders of Fresenius SE & Co. KGaA – adjusted for a non-taxable investment gain at Fresenius Medical Care and for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG; 2011 before special items due to MEB and CVR accounting

Fresenius Group: Financial Results by Business Segment

H1/12	Fresenius Medical Care	Fresenius Kabi	Fresenius Helios	Fresenius Vamed
Sales Growth	US\$6,677 m 9% ¹	€2,234 m 13%	€1,540 m 19%	€333 m 6%
EBIT Growth	US\$1,092 m 14%	€452 m 10%	€151 m 23%	€13 m 8%

¹ Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

Fresenius Kabi: Update H1/12


- 9% organic sales growth – exceeding outstanding H1/11, excellent contribution from all regions
 - +10% outside North America
 - +9% in North America
- U.S. I.V. drug shortage situation continued
 - Shortage list July: 94 drugs, 31 marketed by Kabi (January 2012: 86 drugs, 28 marketed by Kabi)
- Acquisition of Fenwal creates a global leader in transfusion technology; provides ideal platform for future growth
- 2015 mid-term targets¹ increased due to Fenwal acquisition: Sales ~€6 bn (before: ~€5.5 bn)
EBIT >€1.1 bn (before: >€1 bn)



¹ At current exchange rates

Fresenius Helios: Update H1/12

- 5.4% organic sales growth;
230 bps EBIT margin increase to 11.9% in established clinics – excellent operating results and one-time gain
- Integration of acquired hospitals Duisburg and Damp on track
- Hospital privatization market update:
 - Privatized hospital revenue 2012 YTD: ~€450 m – significantly exceeding FY/11 (~€365 m) and FY/10 (~€230 m)
 - Projects >€250 million revenue pending
- Assessing options to combine HELIOS with RHÖN-KLINIKUM AG – expect to take a decision in August



Fresenius Vamed: Update H1/12

- Sales and EBIT in line with expectations and guidance
- Order intake in project business at €156 million; acceleration in H2/12 expected
- Acquisition of H.C. Hospital Consulting / Florence:
 - Italian market entry for maintenance / technical management of medical equipment
 - 2011 sales: approx. €30 million; consolidated as of Jan 1, 2012
 - Provider for approx. 130 health care facilities
 - More than 30 years of experience in Italian health care market

Q2 order intake: Turnkey project at San Fernando General Hospital – Republic of Trinidad and Tobago



Fresenius Group: Financial Outlook by Business Segment Fully Confirmed

		Previous	New	
Fresenius Kabi	Sales growth ¹	7% – 9%	confirmed	✓
	EBIT margin	20% – 20.5%	confirmed	✓
Fresenius Helios	Sales growth ¹	3% – 5%	confirmed	✓
	EBIT	€310 m – €320 m (upper end)	confirmed	✓
Fresenius Vamed	Sales growth	5% – 10%	confirmed	✓
	EBIT growth	5% – 10%	confirmed	✓
Fresenius Biotech	EBIT	~-€25 m – -€30 m	confirmed	✓

¹ organic

Fresenius Group: Financial Outlook Fully Confirmed

	Previous	New	
Revenue growth ¹ at constant currency	12% – 14%	confirmed	✓
Net income growth ² at constant currency	14% – 16%	confirmed	✓
Capex	~5% of Group sales	confirmed	✓

¹ Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

² Net income attributable to shareholders of Fresenius SE & Co. KGaA – adjusted for a non-taxable investment gain at Fresenius Medical Care Outlook before one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG

Attachments



Fresenius Group: Profit and Loss Statement

€m	Q2/12	H1/12	Growth Q2/12 YoY	
			actual rates	constant rates
Sales ¹	4,817	9,236	20%	14%
EBIT ²	779	1,440	23%	15%
Net interest	-166	-313	-18%	-11%
Income taxes	-191	-347	-25%	-16%
Net income ³	234	434	21%	14%

¹ Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

² Adjusted for one-time costs of €7 million in Q2 2012 related to the offer to the shareholders of RHÖN-KLINIKUM AG.






³ Net income attributable to shareholders of Fresenius SE & Co. KGaA – adjusted for a non-taxable investment gain at Fresenius Medical Care and for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG, 2011 before special items due to MEB and CVR accounting

Fresenius Group: Cash Flow

€m	Q2/12	LTM Margin ¹	Q2/11	LTM Margin ¹	Growth YoY
Operating Cash Flow	598	12.3%	372	10.8%	61%
Capex (net)	-206	-4.7%	-145	-4.3%	-42%
Free Cash Flow (before acquisitions and dividends)	392	7.6%	227	6.5%	73%
Acquisitions (net)	-100		-597		83%
Dividends	-350		-288		-22%
Free Cash Flow (after acquisitions and dividends)	-58	-6.3%	-658	-3.1%	91%

¹ Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care

Cash Flow Development LTM

€m	Operating CF		Capex (net)		Free Cash Flow ¹	
	LTM H1/12	LTM Margin	LTM H1/12	LTM Margin	LTM H1/12	LTM Margin
	545	12.9%	(181)	(4.3%)	364	8.6%
	252	8.7%	(165)	(5.7%)	87	3.0% ³
	-32	-4.2%	(8)	(1.1%)	-40	-5.3%
Corporate/ Other	-1	n/a	(13)	n/a	-14	n/a
 excl. FMC	764	10.4%²	(367)	(4.6%)	397	5.8%²
 Group	2,175	12.3%	(824)	(4.7%)	1,351	7.6%

¹ Before Acquisitions and Dividends

² Incl. FMC dividend


³ Understated: 4.4% excluding €41 million of capex commitments from acquisitions

Margin = in % of sales

Fresenius Group: Debt and Interest Ratios

	Jun 30, 2012	Dec 31, 2011
Debt (€m) thereof 52% US\$ denominated	12,035	9,799
Net debt (€m)	10,068	9,164
Net debt/EBITDA	2.75 ^{1,2}	2.83
EBITDA/Interest	5.8	6.1

Net debt/EBITDA



¹ Pro forma Liberty Dialysis Holdings, Inc. and Damp Group

² Before one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG

Debt excludes Mandatory Exchangeable Bonds which came to maturity on August 14, 2011

Fresenius Kabi: Strong Organic Sales Growth

€m	H1/12	H1/11	Organic Growth
Infusion Therapy	500	443	10%
I.V. Drugs	847	732	10%
Clinical Nutrition	648	560	12%
Medical Devices/ Transfusion Technology	239	236	1%
Total sales	2,234	1,971	9%

Fresenius Kabi: Strong Organic Sales Growth

€m	H1/12	H1/11	Organic Growth
Europe	974	909	6%
North America	609	519	9%
Asia-Pacific	415	332	15%
Latin America/Africa	236	211	14%
Total sales	2,234	1,971	9%

Fresenius Kabi: Excellent EBIT Improvement

€m	H1/12	H1/11	Growth
Europe Margin	192 19.7%	191 21.0%	1%
North America Margin	250 41.1%	200 38.5%	25%
Asia-Pacific/Latin America/Africa Margin	131 20.1%	104 19.2%	26%
Corporate and Corporate R&D	-121	-84	-44%
Total EBIT Margin	452 20.2%	411 20.9%	10%

Fresenius Helios: Strong Sales and EBIT Growth

€m	H1/12	H1/11	Growth
Total sales	1,540	1,293	19%
EBIT			
Established clinic portfolio	162	124	31%
Margin	11.9%	9.6%	
Acquisitions / Divestitures (consolidation / deconsolidation <1 yr)	-11	-1	
Total EBIT	151	123	23%
Margin	9.8%	9.5%	

Fresenius Helios: 2011 Clinic Development Plan

	Years in portfolio							Total
	<1	1	2	3	4	5	>5	
No. of clinics	1	1	-	6	4	7	25	43
Revenue (€m)	16	34	-	183	271	172	1,662	2,336
Target								
EBITDA margin (%)	-	3.0	6.0	9.0	12.0	15.0	15.0	
EBITDA (€m)	-	1.0	-	16.4	32.5	25.7	249.2	324.8
Reported								
EBITDA margin (%)	-	-2.6	-	2.9	13.2	11.2	16.9	14.4
EBITDA (€m)	-3.2	-0.9	-	5.3	35.7	19.2	280.3	336.4
No. of clinics > target	-	-	-	3	2	3	15	23
No. of clinics < target	-	1	-	3	2	4	10	20

IFRS

Fresenius Helios: Performance Indicators

	H1/12	H1/11	Change
No. of hospitals	75	65 ¹	15%
- Acute care clinics	51	45	13%
- Post-acute care clinics	24	20	20%
No. of beds	23,615	20,112 ¹	17%
- Acute care clinics	18,824	16,690	13%
- Post-acute care clinics	4,791	3,422	40%
Admissions²			
- Acute care (inpatient)	361,993	314,724	15%
Occupancy²			
- Post-acute care	85%	79%	
Average length of stay (days)			
- Acute care	6.7	6.7	
- Post-acute care ²	27.6	29.6	

¹ Dec 31, 2011

² Clinics in Germany

Fresenius Vamed: Sales Growth and EBIT in line with Expectations

€m	H1/12	H1/11	Growth
Project business	184	202	-9%
Service business	149	111	34%
Total sales	333	313	6%
Total EBIT	13	12	8%
Margin	3.9%	3.8%	
Order intake¹	156	164	-5%
Order backlog¹	816	845²	-3%

¹ Project business only

² Dec 31, 2011

Share Information

Share key facts

Number of shares ¹	177,698,622
WKN / ISIN	578560 / DE0005785604
Ticker symbol	FRE
Bloomberg symbol	FRE GR
Reuters symbol	FREG.de

ADR key facts

Ratio	8 ADRs = 1 ordinary share
ADR CUSIP / ISIN	35804M105 / US35804M1053
Ticker symbol	FSNUY
Exchange	OTC-market
Structure	Sponsored Level I ADR
Depository bank	Deutsche Bank

¹ as of July 31, 2012

Financial Calendar

31.10.2012	Report on 1 st – 3 rd quarter 2012
26.02.2013	Report on Fiscal Year 2012
30.04.2013	Report on 1 st quarter 2013
17.05.2013	Annual General Meeting, Frankfurt/Main
30.07.2013	Report on 1 st half 2013
05.11.2013	Report on 1 st – 3 rd quarter 2013

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA

Telephone: +49 6172 608-2485

e-mail: Birgit.Grund@fresenius.com

For further information and current news: <http://www.fresenius.com>